On 5/31/24, CASI Pharmaceuticals Inc (NASDAQ: CASI) stock enjoyed a major increase of 11.7%, closing at $3.86. Trading volume in this advance was normal. Relative to the market the stock has been weak over the last nine months but has risen 11.7% during the last week.
Current PriceTarget Research Rating
CASI is expected to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
CASI Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. CASI Pharmaceuticals has a slightly negative Power Rating of 39 and a poor Appreciation Score of 18, with the Lowest Value Trend Rating the result.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment